Content and activities of UGT2B7 in human liver in vitro and predicted in vivo: a bottom-up approach

Chen Xu, Jie Gao, Hai-Feng Zhang, Na Gao, Yuan-yuan Guo, Yan Fang, Qiang Wen, Hai-Ling Qiao

Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, People’s Republic of China
Running Title Page

Running title: Content and activities of UGT2B7 in human liver

Corresponding author: Hai-Ling Qiao, Professor

Institute of Clinical Pharmacology, Zhengzhou University

40 Daxue Road, Zhengzhou, 450052, China

Tel: 86-371-6665-8363; Fax: 86-371-6665-8363; Email: qiaohl@zzu.edu.cn

Number of text pages: 36

Number of tables: 3

Number of figures: 6

Number of references: 49

Number of words in Abstract: 248

Number of words in Introduction: 693

Number of words in Discussion: 1259

Abbreviations: AFE, average fold-error; AZT, zidovudine; CC, correction coefficient; CL_{2B7}, CL_{int} at the isoform level; CL_{4f}, predicted hepatic clearance; CL'_{it}, corrected predicted hepatic clearance; CL_{int}, intrinsic clearance; CL_{L}, CL_{int} at the liver level; CL_{LT}, CL_{int} at the liver tissue level; CL_{M}, CL_{int} at the microsomal level; CYPs, cytochrome P450 enzymes; HLMs, human liver microsomes; IFE, individual fold-error; Km, Michaelis constant; PC_{L}, protein content at the liver level; PC_{LT}, protein content at the liver tissue level; PC_{M}, protein content at the microsomal level; PXR, pregnane X receptor; SNPs, single nucleotide polymorphisms; UGTs, UDP-glucuronosyltransferases; V_{2B7}, V_{max} at the isoform level; V_{L}, V_{max} at the liver level; V_{LT}, V_{max} at the liver tissue level; V_{M}, V_{max} at the microsomal level; V_{max}, maximum velocity.
Abstract

UDP-glucuronosyltransferase 2B7 (UGT2B7) is one of the most significant isoforms of UGTs in human liver. This research measured UGT2B7 protein content and activities including $V_{\text{max}}$ and $CL_{\text{int}}$ in human liver at isoform, microsomal, liver tissue, and liver levels and identified the factors that influence expression. We determined absolute protein content by LC-MS/MS and activities using the probe drug Zidovudine in 82 normal human liver microsomes. Using a bottom-up method for derivation, we showed UGT2B7 content at the microsomal, liver tissue, and liver levels, as well as activities at the isoform, microsomal, liver tissue, and liver levels in vitro, and predicted hepatic clearance in vivo, with median, range, variation, and 95 and 50% prediction intervals. With regard to the intrinsic activities, the $V_{\text{max}}$ had a median (range) of 7.5 (2-24) pmol/min/pmol 2B7 and the $CL_{\text{int}}$ was 0.08 (0.02-0.31) µl/min/pmol 2B7. Determinations at liver level showed larger variations than at microsomal level, so it was more suitable for evaluating individual differences. By analyzing factors that affect UGT2B7, we found that: 1) the content at the liver tissue and liver levels correlated positively with activities; 2) the mutant heterozygotes of -327G>A, -900A>G, -161C>T may lead to decreased protein content and increased intrinsic $CL_{\text{int}}$; and 3) the transcription factor pregnane X receptor (PXR) mRNA expression level was positively associated with the measured protein content. In all, we showed protein content and activities at different levels and the factors that influence content to provide valuable information for UGT2B7 research and clinically individualized medication.
Introduction

UDP-glucuronosyltransferases (UGTs) are important phase II metabolic enzymes. Glucuronidation is beneficial to detoxification and excretion of the substrates. UGTs are divided into 3 subfamilies: UGT1A, 2A, and 2B. UGT2B7 is one of the most important UGT isoform in human liver and participates in the metabolism of numerous drugs (Williams et al., 2004). Zidovudine (AZT) is an antiviral drug used clinically for the treatment of patients with acquired immunodeficiency syndrome (AIDS), with large individual differences in effectiveness (Soares et al., 2013). AZT is metabolized via UGT2B7 in liver and then excreted through kidney and is a widely used probe of UGT2B7 activity (Court et al., 2003; Engrakul et al., 2005).

Stable isotope dilution-multiple reaction monitoring-mass spectrometry (SID-MRM MS) has become an ideal method for absolute protein quantification. Our team has completed absolute protein quantification of 10 cytochrome P450 enzymes (CYPs) using 100 normal human liver samples (Zhang et al., 2016b). UGTs, like CYPs, are important metabolic enzymes in liver, but have been less studied than CYPs. Few studies have undertaken absolute protein quantification of UGT2B7 (Ohtsuki et al., 2012; Sato et al., 2012; Fallon et al., 2013; Achour et al., 2014; Sato et al., 2014; Margaillan et al., 2015a). Therefore, large tissue samples with clear background are needed to obtain accurate measurements of UGT2B7 content in human livers.

Using a bottom-up model to extrapolate quantitative data from in vitro to in vivo has shown value for predicting the pharmacokinetics of drugs (Rostami-Hodjegan, 2012; Bell et al., 2017). However, due to constraints on ethics and techniques, it is hard to obtain all required parameters from the same case. Therefore, few studies have used this method to determine simultaneously the individual values of content and activity for enzyme isoforms. Because of large variations in
isoform content per mg of human liver microsomal protein (HLMs), isoform level (per pmol of isoform) rather than traditional microsomal level (per mg of microsomal protein) has been used to determine the intrinsic activities of isoforms (Zhang et al., 2016b). There are few reports on activities at the isoform level of UGT2B7, which may lead to a misunderstanding of its intrinsic activities and affect individualized medication.

The regulatory mechanisms of UGT2B7 expression are complex and not well established. Single-nucleotide polymorphisms (SNPs) can impact the formation of functional enzymes and their enzymes activities. UGT2B7 is considered to be polymorphic (Colic et al., 2015). We previously analyzed the effects of genetic polymorphisms on CYPs (Gao et al., 2016b; Gao et al., 2017a), but UGT2B7 has not been similarly characterized. In addition, UGT2B7 has the highest expression in liver, indicating that some liver-specific factors are needed for physiological transcriptional responses (Yueh et al., 2011). The pregnane X receptor (PXR) is a member of the nuclear receptor family and regulates the expression of enzymes (Zhou et al., 2005). According to clinical reports, UGT2B7 often has been considered as a gene responsive to PXR, as indicated by the ability of rifampin, a PXR ligand, to induce expression (Jeong et al., 2008). But few studies on the regulation of UGT2B7 expression by PXR have been performed using human liver samples. Although many studies focus on cell experiments which are able to identify the molecular regulatory mechanisms by which PXR acts on UGT2B7 expression, HLMs can better reflect the in vivo situation in humans (Gardner-Stephen et al., 2004; Liu et al., 2014; Moscovitz et al., 2018). Therefore, it is meaningful to evaluate the impact of gene polymorphisms and the transcription factor PXR on UGT2B7 in normal liver samples, which can help us to understand UGT2B7 more thoroughly.
In summary, based on 82 normal human liver samples, our study reports the protein content and activities of UGT2B7 at different levels by using a bottom-up method to provide more accurate data that helps establish UGT2B7 content and activities parameters. We also explored the impacts of gene polymorphisms and the transcription factor PXR on UGT2B7 expression, in order to explore the regulatory mechanisms for UGT2B7 expression and the reasons for the individual differences in content. We hope this work can provide a reference for population-based pharmacokinetic experimental designs and aid in establishing in vitro to in vivo pharmacokinetic estimates for new drugs.

Materials and Methods

Reagents and Equipment. Tris, dithiothreitol, iodoacetamide, and sequencing grade trypsin were from Promega (Wisconsin, USA). Bovine serum albumin (BSA), uridine diphosphate glucuronic acid (UDPGA) were from Sigma (Deisenhofen, Germany). AZT was from Maike Pharmaceutical Co., Ltd. (Xiamen, China). Zidovudine-glucuronide was from Toronto Research Chemicals Inc (Toronto, Canada). EDTA was from Xiangzhong Institute of Geology (Loudi, China). The genomic DNA purification kit was from ComWin Biotech Co., Ltd. (Beijing, China). RNAiso Plus kit, PrimeScript RT reagent kit with gDNA Eraser, and TB Green Premix Ex Taq II kit were from Takara Biotech Co., Ltd. (Nogihigashi, Japan). All organic solvents were of HPLC grade purity and were from Siyou Chemical Reagent Co., Ltd. (Tianjin, China). All other chemicals and reagents were commercially available with guaranteed purity.

The Easy-nLC-TSQ vantage mass spectrometer (Thermo Fisher Scientific, USA), the high-performance liquid chromatography (HPLC; Agilent 1100, USA) and 7500 Fast Real-Time
PCR system (Applied Biosystems, USA) were used.

**Human Liver Samples and Liver Microsomes.** The 82 human liver samples were obtained at the First Affiliated Hospital and People's Hospital of Zhengzhou University during 2012 and 2014, including 33 males and 49 females. The details of demographic information have been described previously (Zhang et al., 2015b). The study was approved by the ethics committee of the Zhengzhou University, and each patient signed a written informed consent. All experiments were conducted in accordance with the Declaration of Helsinki. All donors had normal liver function. All the liver tissues were taken from the normal liver tissue adjacent to surgical biopsies and passed pathological examination, and were stored in liquid nitrogen until used. Differential centrifugation was used to prepare HLMs as previously described (Zhang et al., 2015b) and stored at -80°C until used. Microsomal protein concentrations were determined by Bradford method (Bradford, 1976). The microsomal protein per gram of liver (MPPGL) content was determined as previously described (Zhang et al., 2015b).

**Quantification of UGT2B7 Protein Contents in HLMs.** Quantitative analysis was achieved on the nano-liquid chromatography–tandem mass spectrometry (LC-MS/MS) using our established quantitative concatemer (QconCAT) strategy combined with SID-MRM MS (Wang et al., 2015). Briefly, first, the synthesized peptides ASGNLIPQEK and TILDELVQR composed of a QconCAT protein were chosen to quantify the QconCAT protein. The two peptides were accurately quantified by amino acid analysis. The QconCAT protein was a concatemer composed of signature peptides of target proteins, and the signature peptide of UGT2B7 was IEIYPTSLTK.

Secondly, QconCAT plasmids were transfected into *Escherichia coli* to induce expression, with DEME medium containing $^{13}$C$_6$ L-lysine and $^{13}$C$_6$ L-arginine. The QconCAT protein was purified
by affinity chromatography and verified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS).

Thirdly, an in-solution digestion method was carried out. The recombinant QconCAT protein and HLMs protein were denatured using 8 M urea, reduced using dithiothreitol (10 mM, 37℃, 4 h), then alkylated using iodoacetamide (40 mM, room temperature, dark, 30 min), diluted using 7 volumes of 50 mM NH₄HCO₃ solution, and digested using trypsin at the trypsin to substrate ratio of 1 : 50 (37℃, 26 h).

Fourthly, the ASGNLIPQEK which had higher MS response signal was selected to quantify QconCAT protein by using nano-high performance liquid chromatography coupled to multiple reaction monitoring mass spectrometry (nanoHPLC-MRM MS) analysis. The limit of quantitation and linear range were assessed and concentration of the QconCAT protein was calculated according to the linear curve equation.

Lastly, liver samples were analyzed by nano LC-MRM MS using an easy nano-LC coupled to a TSQ vantage triple quadrupole mass spectrometer. The nano LC-MS/MS methodology was reported in our previous work (Wang et al., 2015).

**Determination of UGT2B7 Metabolic Activities in HLMs.** Concentrations of AZT standard solutions ranged from 195 μM to 12.5 mM. Incubations (100 μl) contained PBS (50 μM, pH 7.4, 2% BSA), microsomal protein (0.2 mg/ml), alamethicin (50 μg/mg protein) and sucrose (0.25 M). A series of AZT standard solutions were added to tubes in advance and dried with nitrogen at room temperature. The mixtures were pre-incubated for 5 min at 37℃, and UDPGA (5 mM) added for additional 60 min. Incubations were terminated after adding 10 μl perchloric acid and placing on ice. HLMs proteins were precipitated and discarded by centrifugation and the supernatants (15 μl)
were analyzed by HPLC.

The HPLC apparatus is composed of an autoinjector, binary pump, column, and UV absorbance detector set at a wavelength of 266 nm. The mobile phase was a mixture of acetonitrile and potassium phosphate buffer (20 mM, pH 2.2) at a flow rate of 1 ml/min. The individual values of Michaelis constant ($K_{m}$) and maximum velocity ($V_{max}$) are determined by nonlinear regression analysis using GraphPad Prism 6.0 software. The intrinsic clearance ($CL_{int}$) is obtained from the ratio of $V_{max}$ to $K_{m}$.

**Bottom-up Calculation of Hepatic Clearance.** The bottom-up process included several equations (Steere et al., 2015; Gao et al., 2016a). The protein content and activity are determined in the same way. It should be noted that the most microscopic level of content is the microsomal level while activities are the isoform level. Here, taking the $CL_{int}$ of UGT2B7 as an example, where $CL_{M}$ and $PC_{M}$ are $CL_{int}$ and protein content at the microsomal level, respectively.

The $CL_{int}$ at the isoform level ($CL_{2B7}$) was calculated as:

$$CL_{2B7} = CL_{M} / PC_{M} \text{ (Equation 1)}$$

The $CL_{int}$ at the liver tissue level ($CL_{LT}$) was calculated as:

$$CL_{LT} = CL_{M} \times MPPGL \text{ (Equation 2)}$$

The $CL_{int}$ at the liver level ($CL_{L}$) was calculated as:

$$CL_{L} = CL_{LT} \times LW / BW \text{ (Equation 3)}$$

Where LW is liver weight and BW is body weight. According to the BW of each patient, the value of LW was obtained by the product of liver volume (LV) and liver density, where LV (ml) = $12.5 \times$ BW (kg) + 536.4 (Wang et al., 2008) and liver density is 1.001 g/ml (Yuan et al., 2008). The derivations of protein content and $V_{max}$ at different levels were similar to clearance.
The hepatic clearance \textit{in vivo} (CL$_H$) of AZT glucuronidation was predicted by the well-stirred model:

$$\text{CL}_H = \frac{(Q_H \times \text{CL}_L \times f_{u,b})}{(Q_H + \text{CL}_L \times f_{u,b})} \quad \text{(Equation 4)}$$

The $f_{u,b}$ here means fraction unbound in blood, the result of which is 0.895 (Luzier and Morse, 1993), and $Q_H$ refers to liver blood flow, which is estimated as 24.5\% (Barter et al., 2013) of the cardiac output ($C_O$). The values of $C_O$ calculated from data for 783 normal Han Chinese males and 805 females. Mean values from each group were chosen based on age and gender of donors in this research.

For verifying the overall accuracy of prediction, the average fold-error (AFE) was calculated as:

$$\text{AFE} = 10^{\left|\frac{\sum \log \text{Predicted mean/Observe overall mean}}{N}\right|} \quad \text{(Equation 5)}$$

The individual accuracy was evaluated based on the individual fold-error (IFE) used to evaluate the individual accuracy was calculated as:

$$\text{IFE} = 10^{\left|\frac{\sum \log \text{Predicted individual value/Observe overall mean}}{N}\right|} \quad \text{(Equation 6)}$$

Where N means the number of separate reports in literature concerning AZT intravenous clearance. Due to the lack of individual data in literature, the observed overall mean was used to estimate IFE. A two-fold bias limit refers to 0.5–2.0 of AFE and IFE values (Gao et al., 2017b).

To make the prediction more accurate, we introduced a correction coefficient (CC), which was the inverse of the AFE (Gao et al., 2016a).

**Genotypes of UGT2B7.** Genomic DNA was isolated from human liver tissue using a genomic DNA purification kit. The 10 SNPs (-112C>T, -1852G>C, -1759A>T, -1684T>C, 16663C>T, -900A>G, -161C>T, 211G>T, 2033A>G, -327G>A) were selected in view of the reports of polymorphisms in Asian ethnic group with frequencies of more than 1\%. All SNPs were
DMD # 82024

determined by Sequenom and SNP MassARRAY methods.

**Determination of the PXR mRNA Level in Human Liver.** The primer sequences of PXR were 5’-ACAGCTGGCTAGCATTCTCA-3’ (forward) and 5’-CTTGCTCTCTGATGGTCCTG-3’ (reverse) (Zhang et al., 2016a). The mRNA levels were determined as described previously (Zhang et al., 2015a). Briefly, total RNA was extracted from human liver tissue using the RNAiso Plus kit. The cDNA for real-time quantitative polymerase chain reaction (qRT-PCR) was synthesized from 1 μg total RNA using a PrimeScript RT reagent kit with gDNA Eraser. The PXR mRNA expression level was detected by two-step qRT-PCR using an ABI 7500 Fast Real-Time PCR system.

**Statistical Analyses.** Because most of data were non-normal distribution, the group data were presented as median (range). Nonparametric Spearman rank correlation analysis was applied to estimate the correlation coefficient ($r$). $0.3 \leq r < 0.5$ means weak correlation; $0.5 \leq r < 0.8$ means moderate correlation; $r \geq 0.8$ means strong correlation. The Mann-Whitney U test was used for pairwise comparison and the Kruskal-Wallis H test was used for multiple pairwise comparisons. A two-sided $P < 0.05$ was considered statistically significant. All statistical analyses were performed with the SPSS17.0 software and GraphPad Prism 6.0 software.

**Results**

1 **Protein content of UGT2B7 at different levels in vitro.**

1.1 **Characteristics of protein content at three levels.**

Table 1 showed the median, range, variation and 95 and 50% prediction intervals (PI) for protein contents at different levels. We obtained the absolute protein content of UGT2B7 in HLMs
by LC-MS/MS. The median (range) of protein content at the microsomal level (PC_M) was 127 (43-251) pmol/mg protein. The ratio of maximum to minimum which represents the variation was 5.8-fold.

The protein content at the liver tissue level (PC_LT) of each sample was the product of individual value of MPPGL and corresponding PC_M. The median (range) of MPPGL was 39 (9.9-128) mg/g. The lowest and highest contents of PC_LT were 1.1 and 22 nmol/g liver and exhibited a 20.0-fold variation, with the median value at 4.5 nmol/g liver.

The median (range) of BW and LW were 64 (30-92) kg and 1337 (912-1688) g. The individual protein content at the liver tissue level (PC_L) was calculated by multiplying the individual value of LW/BW by the corresponding PC_LT. The median of PC_L was 95 nmol/kg, and the variation was 18.5-fold (range from 24 to 445 nmol/kg).

As the most macroscopic level of the three levels, PC_L showed larger individual differences than PC_M. To avoid the impact of outliers, 95 and 50% PI was estimated. All 95% PI were less than 17-fold, and all 50% PI were less than 2.5-fold.

1.2 Correlation between protein contents at different levels.

As shown in Fig. 1, correlations were observed between protein contents at different levels ($P < 0.0001$). PC_M had moderate association with PC_LT and PC_L ($r = 0.644$ and 0.626, respectively). The degree of correlation suggested that there existed quite differences between them, which may be caused by variation in MPPGL. Since the results of LW/BW had little individual variation, there was a strong correlation between PC_LT and PC_L ($r = 0.994$).

2 The metabolic activities of UGT2B7 at different levels in vitro.

2.1 Characteristics of the activities at four levels.
The UGT2B7 metabolic activities at four levels including $V_{\text{max}}$ and $\text{CL}_{\text{int}}$ are shown in Table 2. Using the bottom-up method we calculated the $V_{\text{max}}$ at the isoform, microsomal, liver tissue, and liver levels separately, which were successively considered as $V_{2B7}$, $V_M$, $V_{LT}$, and $V_L$. The median (range) was 7.5 (2-24) pmol/min/pmol 2B7, 0.91 (0.44-2.1) nmol/min/mg protein, 37 (6.6-109) nmol/min/g liver, and 0.76 (0.16-2.3) μmol/min/kg in proper order. The variations were 12.0-, 4.8-, 16.5-, and 14.4-fold.

The median (range) of $K_m$ was 94 (43-182) μM. Similarly, we estimated the $\text{CL}_{2B7}$, $\text{CL}_M$, $\text{CL}_{LT}$, and $\text{CL}_L$, respectively. The values of median (range) were 0.08 (0.02-0.31) μl/min/pmol 2B7, 10.4 (4.6-24.2) μl/min/mg protein, 0.41 (0.072-1.5) ml/min/g liver, and 8.6 (1.8-32) ml/min/kg. The variations were 15.5-, 5.3-, 20.8-, and 17.8-fold.

From the results, $V_{\text{max}}$ and $\text{CL}_{\text{int}}$ at the liver level presented larger variations than obtained at the microsomal level. All 95% PI were less than 12-fold, and all 50% PI were less than 3-fold.

### 2.2 Correlation between the metabolic activities at four levels in vitro.

We separately analyzed the correlation between metabolic activities at four levels (Fig. 2, 3). $V_M$ and $V_{2B7}$ were weakly correlated ($r = 0.401$, $P = 0.0002$). Moderate associations were observed between $V_M$ and $V_{LT}$, $V_L$ ($r = 0.564$, 0.549, $P < 0.0001$). There were also moderate associations between $\text{CL}_M$ and $\text{CL}_{\text{int}}$ at the other three levels ($0.500 \leq r < 0.800$, $P < 0.0002$). Those indicated that the activities at the microsomal level were quite different from those at the other three levels, and could be explained by individual differences in MPPGL.

There was no association between $V_{2B7}$ and $V_{LT}$, $V_L$ ($P > 0.05$). Weak associations were observed between $\text{CL}_{2B7}$ and $\text{CL}_{LT}$, $\text{CL}_L$ ($r = 0.345$, 0.366, $P < 0.002$). Because of the poor correlations between the activities at the isoform level and the liver tissue/liver levels, there were
significant differences between them. This suggested that they exhibit activities from microscopic and macroscopic, respectively.

Since there were few variations in LW/BW, both $V_{\text{max}}$ and $\text{CL}_{\text{int}}$ displayed a strong correlation between liver tissue and liver levels ($r = 0.991$, $P < 0.0001$).

3 Prediction of clearance in vivo.

The median (range) of Co was 5.1 (4.9–6.7) l/min, which was calculated based on age and gender. According to the Co, the median (range) of $Q_{\text{H}}$ was 1259 (1205–1629) ml/min. By using the in vitro to in vivo exploration (IVIVE) method, we predicted the hepatic clearance ($\text{CL}_{\text{H}}$) (Table 3).

The median (range) of $\text{CL}_{\text{H}}$ was 7.6 (1.6–28) ml/min/kg. To assess the accuracy of prediction, $\text{CL}_{\text{H}}$ was compared with the reported observed clearance values in vivo which are 18.33, 21.67, and 27.17 ml/min/kg, respectively (Blum et al., 1988; Stagg et al., 1992; Hoetelmans et al., 1996). The AFE value was 0.401 and 28 (28.05%) of the IFE values were within a 2-fold error range, indicating that the $\text{CL}_{\text{H}}$ was underestimated.

To get more accurate measurements, the parameter CC was introduced (Poulin et al., 2012). As the inverse of AFE, the value of CC was 2.49. Individual $\text{CL}_{\text{H}}$ multiplied by CC to obtain the corresponding corrected hepatic clearance ($\text{CL}'_{\text{H}}$). The median (range) of $\text{CL}'_{\text{H}}$ was 19 (3.9–69) ml/min/kg. The corrected AFE' was 1.000, suggesting the prediction was accurate. There were 61 (74.39%) of IFE' within a 2-fold error range, significantly more than uncorrected cases ($P < 0.0001$). The variation of corrected predicted hepatic clearance was 17.7-fold.

4 Influence factors on protein content and activities.

4.1 Effect of protein content on activities.
We explored the effect of protein content on UGT2B7 metabolic activities (Fig. 4). Moderate associations were observed between content and activities including $V_{\text{max}}$ and $\text{CL}_{\text{int}}$ at the liver tissue and liver levels, respectively ($0.500 \leq r < 0.800, P < 0.0001$). $\text{PC}_M$ and $V_M$ showed a weak correlation ($r = 0.324, P = 0.003$). Unfortunately, there was no association between $\text{PC}_M$ and $\text{CL}_M$.

4.2 Effect of gene polymorphisms on protein content and activities.

10 SNPs were detected to analyze the effect of gene polymorphisms on protein content and activities. Only positive results are shown in Fig. 5. The 80 samples of $-327G>A$ included 30 (37.50%) wild homozygotes, 42 (52.50%) mutant heterozygotes and 8 (10.00%) mutant homozygotes. Compared with the wild homozygotes, $\text{PC}_M$ of mutant heterozygotes were reduced by 23.86% ($P = 0.003$) (Fig. 5A). Since there is linkage disequilibrium between $-900A>G$ and $-161C>T$, both were present in 80 cases including 31 (38.75%) wild homozygotes, 41 (51.25%) mutation heterozygotes and 8 (10.00%) mutation homozygotes. $\text{PC}_M$ values of mutant heterozygotes were decreased by 25.06% ($P = 0.006$) (Fig. 5B, C). All mutation heterozygotes of the $-327G>A$, $-900A>G$, and $-161C>T$ caused $\text{CL}_{\text{2B7}}$ to rise 30.95 and 34.57%, respectively ($P < 0.020$) (Fig. 5D-F). These results suggest that the heterozygous mutations of the three SNPs may affect UGT2B7 protein expression.

4.3 Effect of transcription factor PXR on protein content.

We measured the PXR mRNA levels for determining the effect of PXR on $\text{PC}_M$. The median (range) of PXR mRNA level was 0.041 (0.01-0.178). There was a positive correlation between PXR and $\text{PC}_M$ ($r = 0.326, P = 0.010$) (Fig. 6), indicating that PXR was involved in the regulation of UGT2B7 protein expression.
Discussion

This study determined UGT2B7 content and activities including $V_{\text{max}}$ and $CL_{\text{int}}$ at different levels by a bottom-up method, and explored the factors that influence expression. Protein content was determined at the microsomal, liver tissue, and liver levels, while activities were determined at the isoform, microsomal, liver tissue, and liver levels, along with predicted hepatic clearance.

Our study reported the absolute protein content and intrinsic activities of UGT2B7 based on large sample human liver tissues. The $PC_M$ median (range) was 127 (43-251) pmol/mg protein, and the median (range) of $V_{2B7}$ and $CL_{2B7}$ was 7.5 (2-24) pmol/min/pmol 2B7 and 0.08 (0.02-0.31) µl/min/pmol 2B7, respectively. Compared with the traditional microsomal level, the liver level was more suitable for evaluating individual differences due to larger variation both in content and activities. To explore the factors that influence UGT2B7 expression, we found that both the liver tissue and liver levels were positively correlated with the corresponding activities; the mutant heterozygotes of -327G>A, -900A>G, and -161C>T reduced the UGT2B7 expression and increased the intrinsic activities; the expression level of transcription factor PXR mRNA was positively correlated with the content.

We quantified the protein content of UGT2B7 in individual HLMs by the SID-MRM MS method, and then calculated the contents at the liver tissue and liver levels. Up to now, reported quantitative results of UGT2B7 protein were varied (Ohtsuki et al., 2012; Sato et al., 2012; Fallon et al., 2013; Achour et al., 2014; Sato et al., 2014; Margaillan et al., 2015b). Achour et al. (2014) used the same method to quantify UGT2B7 content in HLMs, and our results differ from theirs. This may be due to the different choices of peptides used as calibrants, and different experimental processes such as denaturation and digestion (Proc et al., 2010; Achour et al., 2017). In addition,
sample size, variation, and population sample may also contribute to differences. For the rare individual values of MPPGL, the protein content of UGT2B7 at the liver tissue and liver levels have not been reported previously. We deduced the values of PC\textsubscript{LT} and PC\textsubscript{L} from PC\textsubscript{M}, and found PC\textsubscript{L} had a larger variation than PC\textsubscript{M}. The three levels represent progression from microscopic to macroscopic, and the liver level showed the greatest macroscopic aspect; thus, the liver level may better reflect individual differences in UGT2B7 content compared with microsomal level.

Using the bottom-up model, we obtained activities \textit{in vitro} at four levels, including isoform, microsomal, liver tissue, and liver levels. We previously analyzed the influence of gene polymorphisms on CYPs activities at different levels (Zhang et al., 2016b). The results further confirmed that isoform level can reflect the real roles of influence factors. However, most studies on UGT2B7 activities were at the traditional microsomal level. We reported the median (range) of V\textsubscript{2B7} and CL\textsubscript{2B7} was 7.5 (2-24) pmol/min/pmol 2B7 and 0.08 (0.02-0.31) \textmu l/min/pmol 2B7, respectively. This lays a foundation for personalized medicine. At the microsomal level, the V\textsubscript{M} we determined was consistent with other studies (Furlan et al., 1999; Boase and Miners, 2002; Rowland et al., 2007). The K\textsubscript{m} values reported in the early literatures were about 1000 \textmu M (Boase and Miners, 2002; Court et al., 2003), but this may be an illusion caused by the release from membranes of long-chain unsaturated fatty acids that then serve as a UGT2B7 competitive inhibitor (Tsoutsikos et al., 2004; Rowland et al., 2007). BSA, which will bind fatty acids, when added to incubations can reduce the K\textsubscript{m} value of UGTs by about 10-fold, without an effect on V\textsubscript{max} (Rowland et al., 2007; Miners et al., 2010). CL\textsubscript{int} was the ratio of V\textsubscript{max} to K\textsubscript{m}. In the early literatures the K\textsubscript{m} was overestimated and the CL\textsubscript{int} was underestimated. We used the optimized experimental protocol which reflected the K\textsubscript{m} and CL\textsubscript{int} more accurately. The four levels also
showed activities from microcosmic to macroscopic. Activities at the liver level are closer to the activities in vivo than the other three levels, and the liver level was more suitable for evaluating individual differences. The traditional microsomal level, in contrast, may hide actual variation in activities because individual differences of MPPGL and protein content were not considered.

The purpose of studies in vitro is to apply results in vivo. We calculated and corrected hepatic clearance in vivo. In the current reports, the aim of predicting AZT hepatic clearance was mainly as an indicator of the experimental methods optimization. Those papers used a few samples without results correction, and the predicted values were lower than observed values (Boase and Miners, 2002; Rowland et al., 2007). Although similar results were found in CL_{H}, the CL'_{H} was accurate after correction. Our predicted data could provide information for estimating hepatic clearance as part of the process of new drug research and development.

At the end of this study, we discussed the factors that influence of UGT2B7 expression. Literatures on the effect of UGT2B7 content on activities are at the microsomal level, using relative protein content or the probe drug morphine (Court et al., 2003; Sato et al., 2012). Our research can yield more accurate results due to better experimental design. At the liver tissue and liver levels, which were closer to the activities in vivo, we found that protein content was positively associated with the corresponding \( V_{\text{max}} \) and \( \text{CL}_{\text{int}} \). This intuitively confirmed that protein content was involved in affecting UGT2B7 activities in vivo.

Many studies focus on disease susceptibility genes of UGTs (Lin et al., 2005; Chung et al., 2008; Hu et al., 2016). The data on polymorphisms influencing UGT2B7 content and activities in normal population are not abundant. Our results show that the mutant heterozygotes of -327G>A, -900A>G, and -161C>T were related to the decrease of PC_{M} and the increase of CL_{2B7}. We
deemed that the polymorphisms indirectly affect the CL$_{2B7}$ by regulating the enzyme content. This also suggests the superiority of isoform level measurements in reflecting the factors that influence activity compared with microsomal level.

Currently, there is a little information about the role of the transcription factor PXR in UGT2B7 expression in the complex environment of the human body. We found that PXR had a positive regulatory effect on UGT2B7 protein expression by HLMs. This is consistent in that UGT2B7 is a responsive gene to PXR in clinical reports and that there is a positive correlation between PXR and UGT2B7 mRNA in HLMs (Jeong et al., 2008; Liu et al., 2014). However, there are reports with cell experiments which are inconsistent with our results (Gardner-Stephen et al., 2004; Moscovitz et al., 2018). We deemed that the regulations of UGT2B7 in human body ultimately reflects the combined effects of influencing factors, and HLMs more closely reflect the real situation. Cell experiments, however, are primarily used as studies of the mechanisms, without considering other factors.

In conclusion, this study supplied an accurate physiological and functional database for UGT2B7 expression in human liver, and filled a gap in UGTs large sample research. We verified the view that activities at the isoform level represent the UGT2B7 intrinsic activities, which provides new ideas for studying metabolic enzymes. Furthermore, we found that the gene polymorphisms of -327G>A, -900A>G, and -161C>T and transcription factor PXR may be involved in the regulation of UGT2B7 protein expression. Further exploration of the regulation mechanisms is needed for a better understanding UGT2B7. The predicted hepatic clearance is valuable for predicting pharmacokinetic parameters in vivo, and we will continue to confirm the accuracy in future studies. Above all, we hope data in this paper can guide the design for
DMD # 82024

population pharmacokinetic studies and new drug research, and provide information for the further understanding of UGT2B7.
Authorship Contributions

Participated in research design: Qiao.

Conducted the experiments: Xu, Jie Gao, Zhang, Na Gao, Guo, Fang.

Contributed new reagents or analytic tools: Zhang, Na Gao, Wen.

Performed data analysis: Xu, Jie Gao.

Wrote or contributed to the writing of the manuscript: Xu, Jie Gao.
References


Hoetelmans RM, Burger DM, Meenhorst PL, and Beijnen JH (1996) Pharmacokinetic


that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. *Biochem Pharmacol* **67:**191-199.


Footnotes

This work supported by the National Natural Science Foundation of China [Nos. 81473279 and 81673507]

Chen Xu and Jie Gao contributed equally to this work.
**Legends for Figures**

**Fig. 1.** Correlation between protein contents at the microsomal, liver tissue, and liver levels. (A) Correlation between PC\(_M\) and PC\(_{LT}\). (B) Correlation between PC\(_M\) and PC\(_L\). (C) Correlation between PC\(_{LT}\) and PC\(_L\). The PC\(_M\), PC\(_{LT}\), and PC\(_L\) are defined as protein content at the microsomal, liver tissue, and liver levels. PC\(_M\) was measured by LC-MS/MS in 82 normal human liver microsomes. When there was statistical difference (\(P < 0.05\)), Spearman rank order correlation (\(r\)) and \(P\) value is displayed.

**Fig. 2.** Correlation between \(V_{\text{max}}\) at the isoform, microsomal, liver tissue, and liver levels. (A-C) Correlation between \(V_M\) and \(V_{2B7}\), \(V_{LT}\), \(V_L\). (D-E) Correlation between \(V_{2B7}\) and \(V_{LT}\), \(V_L\). (F) Correlation between \(V_{LT}\) and \(V_L\). The \(V_{2B7}\), \(V_M\), \(V_{LT}\), and \(V_L\) are defined as \(V_{\text{max}}\) at the isoform, microsomal, liver tissue, and liver levels. The \(V_M\) was measured by Zidovudine (AZT) as a probe in 82 normal human liver microsomes. When there was statistical difference (\(P < 0.05\)), Spearman rank order correlation (\(r\)) and \(P\) value is displayed.

**Fig. 3.** Correlation between CL\(_{\text{int}}\) at the isoform, microsomal, liver tissue, and liver levels. (A-C) Correlation between CL\(_M\) and CL\(_{2B7}\), CL\(_{LT}\), CL\(_L\). (D-E) Correlation between CL\(_{2B7}\) and CL\(_{LT}\), CL\(_L\). (F) Correlation between CL\(_{LT}\) and CL\(_L\). The CL\(_{2B7}\), CL\(_M\), CL\(_{LT}\), and CL\(_L\) are defined as CL\(_{\text{int}}\) at the isoform, microsomal, liver tissue, and liver levels. The CL\(_M\) was measured by Zidovudine (AZT) as a probe in 82 normal human liver microsomes. When there was statistical difference (\(P < 0.05\)), Spearman rank order correlation (\(r\)) and \(P\) value is displayed.

**Fig. 4.** Correlation between protein content and metabolic activities at the microsomal, liver tissue, and liver levels. (A-C) Correlation between protein content and \(V_{\text{max}}\) at the microsomal, liver tissue, and liver levels. (D-F) Correlation between protein content and CL\(_{\text{int}}\) at the microsomal, liver tissue, and liver levels.
liver tissue, and liver levels. The \( PC_M \), \( V_M \), and \( CL_M \) represent protein content, \( V_{\text{max}} \), and \( CL_{\text{int}} \) at the microsomal level, respectively. The \( PC_{LT} \), \( V_{LT} \), and \( CL_{LT} \) represent protein content, \( V_{\text{max}} \), and \( CL_{\text{int}} \) at the liver tissue level, respectively. The \( PC_L \), \( V_L \), and \( CL_L \) represent protein content, \( V_{\text{max}} \), and \( CL_{\text{int}} \) at the liver level, respectively. The \( PC_M \) was measured by LC-MS/MS while the \( V_M \) and \( CL_M \) were measured by Zidovudine (AZT) as a probe in 82 normal human liver microsomes. When there was statistical difference \( (P < 0.05) \), Spearman rank order correlation \( (r) \) and \( P \) value is displayed.

**Fig. 5.** Effect of UGT2B7 gene polymorphisms on protein content and intrinsic activity. Compared with the wild homozygotes, \( PC_M \) of mutant heterozygotes of (A) -327G>A, (B) -900A>G, and (C) -161C>T were decreased. Compared with the wild homozygotes, \( CL_{2B7} \) of mutant heterozygotes of (D) -327G>A, (E) -900A>G, and (F) -161C>T were increased. \( PC_M \), protein content at the microsomal level; \( CL_{2B7} \), \( CL_{\text{int}} \) at the isoform level. -327G>A \( (GG, n = 31; GA, n = 42; AA, n = 9); -900A>G and -161C>T had linkage disequilibrium \( (AA \text{ or } CC, n = 32; AG \text{ or } CT, n= 41; GG \text{ or } TT, n = 9) \). The Mann-Whitney U test and the Kruskal-Wallis H test were used for nonparametric test. The black horizontal lines represent the median with interquartile range.

**Fig. 6.** Effect of transcription factor PXR on protein content. The mRNA level of PXR was positive correlated with \( PC_M \) \( (n = 62) \). PXR, pregnane X receptor; \( PC_M \), protein content at the microsomal level. When there was correlation of statistical difference \( (P < 0.05) \), Spearman rank order correlation \( (r) \) and \( P \) value is displayed.
### Tables

**Table 1 Characteristics of protein content at the microsomal, liver tissue, and liver levels in human liver microsomes (n = 82).**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Median</th>
<th>Range</th>
<th>95% PI</th>
<th>50% PI</th>
</tr>
</thead>
<tbody>
<tr>
<td>( PC_M ) (pmol/mg protein)</td>
<td>Range</td>
<td>127</td>
<td>43-251</td>
<td>46-247</td>
</tr>
<tr>
<td>Ratio</td>
<td></td>
<td>5.8</td>
<td>5.4</td>
<td>1.8</td>
</tr>
<tr>
<td>( PC_{LT} ) (nmol/g liver)</td>
<td>Range</td>
<td>4.5</td>
<td>1.1-22</td>
<td>1.2-18</td>
</tr>
<tr>
<td>Ratio</td>
<td></td>
<td>20</td>
<td>15.0</td>
<td>2.1</td>
</tr>
<tr>
<td>( PC_L ) (nmol/kg)</td>
<td>Range</td>
<td>95</td>
<td>24-445</td>
<td>25-417</td>
</tr>
<tr>
<td>Ratio</td>
<td></td>
<td>18.5</td>
<td>16.7</td>
<td>2.2</td>
</tr>
</tbody>
</table>

\( PC_M \), protein content at the microsomal level; \( PC_{LT} \), protein content at the liver tissue level; \( PC_L \), protein content at the liver level; PI: prediction intervals.

Ratio, the ratio of the maximum to the minimum.
Table 2 Characteristics of the activities at the isoform, microsomal, liver tissue, and liver levels in human liver microsomes (n = 82).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Median</th>
<th>Range</th>
<th>95% PI</th>
<th>50% PI</th>
</tr>
</thead>
<tbody>
<tr>
<td>( V_{2B7} ) (pmol/min/pmol 2B7)</td>
<td>Range</td>
<td>7.5</td>
<td>2-24</td>
<td>3.7-23</td>
</tr>
<tr>
<td></td>
<td>Ratio</td>
<td>12.0</td>
<td>6.2</td>
<td>1.8</td>
</tr>
<tr>
<td>( CL_{2B7} ) (µl/min/pmol 2B7)</td>
<td>Range</td>
<td>0.08</td>
<td>0.02-0.31</td>
<td>0.03-0.23</td>
</tr>
<tr>
<td></td>
<td>Ratio</td>
<td>15.5</td>
<td>7.7</td>
<td>2.0</td>
</tr>
<tr>
<td>( V_{M} ) (nmol/min/mg protein)</td>
<td>Range</td>
<td>0.91</td>
<td>0.44-2.1</td>
<td>0.5-1.9</td>
</tr>
<tr>
<td></td>
<td>Ratio</td>
<td>4.8</td>
<td>3.8</td>
<td>1.4</td>
</tr>
<tr>
<td>( K_{m} ) (µM)</td>
<td>Range</td>
<td>94</td>
<td>43-182</td>
<td>47-165</td>
</tr>
<tr>
<td></td>
<td>Ratio</td>
<td>4.2</td>
<td>3.5</td>
<td>1.3</td>
</tr>
<tr>
<td>( CL_{M} ) (µl/min/mg protein)</td>
<td>Range</td>
<td>10.4</td>
<td>4.6-24.2</td>
<td>5-23</td>
</tr>
<tr>
<td></td>
<td>Ratio</td>
<td>5.3</td>
<td>4.6</td>
<td>1.5</td>
</tr>
<tr>
<td>( V_{LT} ) (nmol/min/g liver)</td>
<td>Range</td>
<td>37</td>
<td>6.6-109</td>
<td>9.6-100</td>
</tr>
<tr>
<td></td>
<td>Ratio</td>
<td>16.5</td>
<td>10.4</td>
<td>2.4</td>
</tr>
<tr>
<td>( CL_{LT} ) (ml/min/g liver)</td>
<td>Range</td>
<td>0.41</td>
<td>0.072-1.5</td>
<td>0.12-1.3</td>
</tr>
<tr>
<td></td>
<td>Ratio</td>
<td>20.8</td>
<td>10.8</td>
<td>2.8</td>
</tr>
<tr>
<td>( V_{L} ) (µmol/min/kg)</td>
<td>Range</td>
<td>0.76</td>
<td>0.16-2.3</td>
<td>0.22-2.2</td>
</tr>
<tr>
<td></td>
<td>Ratio</td>
<td>14.4</td>
<td>10.0</td>
<td>2.4</td>
</tr>
<tr>
<td>( CL_{L} ) (ml/min/kg)</td>
<td>Range</td>
<td>8.6</td>
<td>1.8-32</td>
<td>2.7-31</td>
</tr>
<tr>
<td></td>
<td>Ratio</td>
<td>17.8</td>
<td>11.5</td>
<td>2.9</td>
</tr>
</tbody>
</table>

\( V_{2B7} \) and \( CL_{2B7} \) represent \( V_{\text{max}} \) and \( CL_{\text{int}} \) at the isoform level; \( V_{M} \) and \( CL_{M} \) represent \( V_{\text{max}} \) and \( CL_{\text{int}} \) at the
microsomal level; $V_{LT}$ and $CL_{LT}$ represent $V_{\text{max}}$ and $CL_{\text{int}}$ at the liver tissue level; $V_{L}$ and $CL_{L}$ represent $V_{\text{max}}$ and $CL_{\text{int}}$ at the liver level; PI: prediction intervals.

Ratio, the ratio of the maximum to the minimum.
Table 3 Characteristics of the $\text{CL}_H$ and $\text{CL}'_H$ in vivo (n = 82).

<table>
<thead>
<tr>
<th></th>
<th>$\text{CL}_H$ (ml/min/kg)</th>
<th>$\text{CL}'_H$ (ml/min/kg)</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Median</strong></td>
<td>7.6</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td><strong>Range</strong></td>
<td>1.6-28</td>
<td>3.9-69</td>
<td>17.7</td>
</tr>
<tr>
<td><strong>95% PI</strong></td>
<td>2.4-27</td>
<td>6-67</td>
<td>11.1</td>
</tr>
<tr>
<td><strong>50% PI</strong></td>
<td>4.4-12</td>
<td>11-30</td>
<td>2.7</td>
</tr>
<tr>
<td><strong>Within 2-fold error (%)</strong></td>
<td>28 (28.05 %)</td>
<td>61 (74.39 %)</td>
<td>****</td>
</tr>
</tbody>
</table>

$\text{CL}_H$, predicted hepatic clearance; $\text{CL}'_H$, corrected predicted hepatic clearance; PI, prediction intervals.

Ratio, the ratio of the maximum to the minimum of $\text{CL}'_H$.

**** $P < 0.0001$ versus $\text{CL}_H$. 

DMD # 82024
Figures

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

$r = 0.326, P = 0.010$